UK weighs up views on genetics and ethics
This article was originally published in Clinica
Executive Summary
Oversimplification of genetics is at the core of the insurance industry's case for genetic testing, [the approval of which] for the purposes of discrimination is deeply inimical to the welfare of our society. It seems remarkably self-defeating for insurers to persist in practices that may damage the very research which will reduce risk in the future."
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.